hotspot -WSS

hotspot

author：focus 2025-10-01 23:38:38 - browse：25

Adam's take main illustration — Molly Ferguson/STAT

Shares of Apellis Pharmaceuticals are rebounding, driven by a growing belief among some investors that the serious safety issue that has derailed Syfovre, the company’s eye disease treatment, is receding.

Declaring the crisis over is premature, but that could change with more uneventful weeks. Apellis has been a takeout target before, and may be again, at an acquisition price nearly twice its current market value.

Apellis shares rose 32% last week, with most of the gains coming Friday on heavy trading volume. The reason: There have been no new cases of retinal occlusive vasculitis, or ROV, reported in people receiving injections of Syfovre.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Supreme Court strikes down use of affirmative action

focus

WSS

How generative AI is inspiring dreams of a health data revolution

Why Novartis is changing the name of its research labs

Duchenne breakthrough therapy leaves behind pioneering families

NIH nominee Bertagnolli will get October confirmation hearing

Anesthesiologist group: stop taking Ozempic before surgery

Weighted lottery helped low

entertainment

hotspot

explore

Guidelines to prevent youth baseball injuries need more muscle

What drug price negotiations mean for Medicare Part D

Psychedelics group wrestles with new pharma identity

Duchenne breakthrough therapy leaves behind pioneering families

After affirmative action ruling, medical educators look to 'holistic review'

Dobbs anniversary: the lost opportunity of abortion as health care

Activists slam private health insurers over coverage restrictions

At least 13 dead in Texas as scorching temps continue

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Trump demands the U.S. pay no more for drugs than other countries … again

hotspot

Activists slam private health insurers over coverage restrictions

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

The 10 drugs up first for Medicare price negotiation

Heart attack and stroke risk calculators need revising

Duchenne breakthrough therapy leaves behind pioneering families

Weighted lottery helped low

entertainment

focus

explore

entertainment